Frederic Hammel

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Fabentech SAS developes immunotherapeutic solutions for emerging infectious diseases as well as for certain drug intoxications. Its products include infography development, Lassa(FBH-003) and other emerging diseases. The company was founded by Bertrand Lepine on June 5, 2009 and is headquartered in Lyon, France.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Nosopharm SAS operates as a biotechnology company. It develops an anti-infective drug platform that is based on the medicinal chemistry of a novel antibiotic class used to cure life-threatening multi-resistant hospital-acquired infections. The company was founded by Philippe Villain-Guillot and Maxime Gualtieri in February 2009 and is headquartered in Nimes, France.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Fabentech SAS developes immunotherapeutic solutions for emerging infectious diseases as well as for certain drug intoxications. Its products include infography development, Lassa(FBH-003) and other emerging diseases. The company was founded by Bertrand Lepine on June 5, 2009 and is headquartered in Lyon, France.

Nosopharm SAS operates as a biotechnology company. It develops an anti-infective drug platform that is based on the medicinal chemistry of a novel antibiotic class used to cure life-threatening multi-resistant hospital-acquired infections. The company was founded by Philippe Villain-Guillot and Maxime Gualtieri in February 2009 and is headquartered in Nimes, France.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Nosopharm SAS operates as a biotechnology company. It develops an anti-infective drug platform that is based on the medicinal chemistry of a novel antibiotic class used to cure life-threatening multi-resistant hospital-acquired infections. The company was founded by Philippe Villain-Guillot and Maxime Gualtieri in February 2009 and is headquartered in Nimes, France.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Nosopharm SAS operates as a biotechnology company. It develops an anti-infective drug platform that is based on the medicinal chemistry of a novel antibiotic class used to cure life-threatening multi-resistant hospital-acquired infections. The company was founded by Philippe Villain-Guillot and Maxime Gualtieri in February 2009 and is headquartered in Nimes, France.

Fabentech SAS developes immunotherapeutic solutions for emerging infectious diseases as well as for certain drug intoxications. Its products include infography development, Lassa(FBH-003) and other emerging diseases. The company was founded by Bertrand Lepine on June 5, 2009 and is headquartered in Lyon, France.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Fabentech SAS developes immunotherapeutic solutions for emerging infectious diseases as well as for certain drug intoxications. Its products include infography development, Lassa(FBH-003) and other emerging diseases. The company was founded by Bertrand Lepine on June 5, 2009 and is headquartered in Lyon, France.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Nosopharm SAS operates as a biotechnology company. It develops an anti-infective drug platform that is based on the medicinal chemistry of a novel antibiotic class used to cure life-threatening multi-resistant hospital-acquired infections. The company was founded by Philippe Villain-Guillot and Maxime Gualtieri in February 2009 and is headquartered in Nimes, France.